Current Report Filing (8-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):   February 23, 2017

 

Nivalis Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware		001-37449		20-8969493
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

 

3122 Sterling Circle, Suite 200 Boulder, Colorado		80301
(Address of principal executive offices)		(Zip Code)

 

Registrant’s telephone number, including area code:   [phone]

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

 

Item 8.01                       Other Events

 

On February 23, 2017, Nivalis Therapeutics, Inc. issued a press release announcing results from the Company’s Phase 2 clinical trial of cavosonstat added to ivacaftor for treatment of cystic fibrosis. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01                       Financial Statements and Exhibits.

 

(d)  Exhibits .

 

Number and Description

 

99.1

Press Release, dated February 23, 2017.

 

2

---

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	NIVALIS THERAPEUTICS, INC.
February 23, 2017		By:	/s/ R. Michael Carruthers
		Name:	R. Michael Carruthers
		Title:	Interim President and Chief Financial Officer

 

3

---

 

EXHIBIT INDEX

 

Exhibit Number		Description
99.1		Press Release, dated February 23, 2017.

 

4

---